

# Christian Thomas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/723465/publications.pdf>

Version: 2024-02-01

68  
papers

992  
citations

623734

14  
h-index

477307

29  
g-index

69  
all docs

69  
docs citations

69  
times ranked

1518  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy. <i>European Urology Focus</i> , 2022, 8, 121-127.	3.1	13
2	Contemporary treatment trends for upper urinary tract stones in a total population analysis in Germany from 2006 to 2019: will shock wave lithotripsy become extinct?. <i>World Journal of Urology</i> , 2022, 40, 185-191.	2.2	20
3	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomographyâ€staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. <i>European Urology Oncology</i> , 2022, 5, 44-51.	5.4	26
4	Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1046.	4.1	4
5	The Androgen Hormone-Induced Increase in Androgen Receptor Protein Expression Is Caused by the Autoinduction of the Androgen Receptor Translational Activity. <i>Current Issues in Molecular Biology</i> , 2022, 44, 597-608.	2.4	5
6	Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	2.5	1
7	Influence of Systemic Therapy on the Expression and Activity of Selected STAT Proteins in Prostate Cancer Tissue. <i>Life</i> , 2022, 12, 240.	2.4	1
8	Acceptance and efficacy of recommended adjuvant radiotherapy in patients with positive lymph nodes at radical prostatectomy: a preference-based study. <i>World Journal of Urology</i> , 2022, 40, 1463-1468.	2.2	2
9	Decreasing Number of Urologists in Urological and Gynaecological Clinics Reflects Decreased Importance for Surgical Indications: German Population-Based Data from 2013 to 2019. <i>Urologia Internationalis</i> , 2022, 106, 1068-1074.	1.3	3
10	Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?. <i>Cancers</i> , 2022, 14, 8.	3.7	12
11	Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). <i>Cancers</i> , 2022, 14, 2073.	3.7	7
12	Treatment of post-prostatectomy urinary incontinence and erectile dysfunction: there is insufficient utilisation of care in German cancer survivors. <i>World Journal of Urology</i> , 2021, 39, 2929-2936.	2.2	7
13	Re: J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. <i>Eur Urol</i> 2020;79:82â€104. <i>European Urology</i> , 2021, 79, e29.	1.9	1
14	OLI-P: Toxicity and efficacy of local ablative radiotherapy in PSMA-PET staged, oligometastatic prostate cancerâ€A phase II trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 115-115.	1.6	1
15	High stromaâ€derived WNT5A is an indicator for lowâ€risk prostate cancer. <i>FEBS Open Bio</i> , 2021, 11, 1186-1194.	2.3	1
16	Development of Incidence and Surgical Treatment of Penile Cancer in Germany from 2006 to 2016: Potential Implications for Future Management. <i>Annals of Surgical Oncology</i> , 2021, 28, 9190-9198.	1.5	6
17	ASO Author Reflections: How Many Centers Do We Need for High-Quality Penile Cancer Surgery in Germany? An Analysis of Total Population Data from 2006 to 2016. <i>Annals of Surgical Oncology</i> , 2021, 28, 9199-9200.	1.5	1
18	Robotic radical prostatectomy: difficult to start, fast to improve? Influence of surgical experience in robotic and open radical prostatectomy. <i>World Journal of Urology</i> , 2021, 39, 4311-4317.	2.2	1

#	ARTICLE	IF	CITATIONS
19	Decreasing Non-Bladder-cancer Mortality After Radical Cystectomy. <i>European Urology Open Science</i> , 2021, 29, 15-18.	0.4	0
20	Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System. <i>Anticancer Research</i> , 2021, 41, 3271-3279.	1.1	7
21	Symptomatic Nephroptosis of the Transplant: First Report of Diagnostic Workup and Successful Minimal-Invasive Treatment. <i>Urologia Internationalis</i> , 2021, 105, 1119-1122.	1.3	0
22	A Systematic Comparison of Antiandrogens Identifies Androgen Receptor Protein Stability as an Indicator for Treatment Response. <i>Life</i> , 2021, 11, 874.	2.4	8
23	Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer. <i>Cancers</i> , 2021, 13, 4854.	3.7	12
24	Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD <sup>®</sup> ) for Localized Prostate Cancer. <i>Urologia Internationalis</i> , 2021, , 1-6.	1.3	5
25	Long-term functional outcomes after robotic vs. retropubic radical prostatectomy in routine care: a 6-year follow-up of a large German health services research study. <i>World Journal of Urology</i> , 2020, 38, 1701-1709.	2.2	24
26	Re: Giorgio Gandaglia G, Peter Albers, Per-Anders Abrahamsson, et al. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. <i>Eur Urol</i> 2019;76:142-50. <i>European Urology</i> , 2020, 77, e30.	1.9	0
27	Centralization tendencies of retroperitoneal lymph node dissection for testicular cancer in Germany? A total population-based analysis from 2006 to 2015. <i>World Journal of Urology</i> , 2020, 38, 1765-1772.	2.2	12
28	Which comorbidity classification is best suited to identify patients at risk for 90-day and long-term non-bladder cancer mortality after radical cystectomy?. <i>World Journal of Urology</i> , 2020, 38, 695-702.	2.2	6
29	Socioeconomic Status-Related Parameters as Predictors of Competing (Non-Bladder Cancer) Mortality after Radical Cystectomy. <i>Urologia Internationalis</i> , 2020, 104, 62-69.	1.3	3
30	Trends in Renal Tumor Surgery in the United States and Germany Between 2006 and 2014: Organ Preservation Rate Is Improving. <i>Annals of Surgical Oncology</i> , 2020, 27, 1920-1928.	1.5	20
31	Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathon I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2019.12.017">https://doi.org/10.1016/j.eururo.2019.12.017</a> . <i>European Urology</i> , 2020, 78, e91.	1.9	0
32	Evaluation of MicroRNAs as Non-Invasive Diagnostic Markers in Urinary Cells from Patients with Suspected Prostate Cancer. <i>Diagnostics</i> , 2020, 10, 578.	2.6	13
33	Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0237248.	2.5	11
34	Online peer-to-peer support for persons affected by prostate cancer: A systematic review. <i>Patient Education and Counseling</i> , 2020, 103, 2107-2115.	2.2	16
35	Quantifying the Relationship Between Increasing Life Expectancy and Nonprostate Cancer Mortality After Radical Prostatectomy. <i>Urology</i> , 2020, 142, 174-178.	1.0	5
36	Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3814.	4.1	15

#	ARTICLE	IF	CITATIONS
37	Validation of a Questionnaire-Suitable Comorbidity Index in Patients Undergoing Radical Cystectomy. <i>Urologia Internationalis</i> , 2020, 104, 567-572.	1.3	7
38	Re: Maria J. Ribal, Philip Cornford, Alberto Briganti, et al. European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2020.04.056">https://doi.org/10.1016/j.eururo.2020.04.056</a> . <i>European Urology Focus</i> , 2020, 6, 1135-1136.	3.1	9
39	AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC. <i>Urologia Internationalis</i> , 2020, 104, 253-262.	1.3	4
40	Decision Regret after Radical Prostatectomy does Not Depend on Surgical Approach: 6-Year Followup of a Large German Cohort Undergoing Routine Care. <i>Journal of Urology</i> , 2020, 203, 554-561.	0.4	26
41	Re: External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer. <i>Journal of Urology</i> , 2020, 203, 420-420.	0.4	2
42	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 560-561.	0.4	0
43	Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. , 2020, 15, e0237248.		0
44	Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. , 2020, 15, e0237248.		0
45	Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. , 2020, 15, e0237248.		0
46	Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 999-1005.	1.6	7
47	Long-Term Mortality in Patients with Positive Lymph Nodes at the Time of Radical Prostatectomy. <i>Urologia Internationalis</i> , 2019, 103, 427-432.	1.3	6
48	Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. <i>Eur Urol</i> 2019;75:552â€“5. <i>European Urology</i> , 2019, 76, e75.	1.9	0
49	Aggressive variant and treatment-related neuroendocrine prostate cancer: two different terms for the same disease?. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 297-300.	0.5	0
50	Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival. <i>International Urology and Nephrology</i> , 2018, 50, 1821-1827.	1.4	12
51	Incidence, Risk Factors and Management of Symptomatic Lymphoceles after Radical Retropubic Prostatectomy. <i>Urology Practice</i> , 2017, 4, 493-498.	0.5	4
52	Ruptured angiomyolipoma of the kidney: a rare differential diagnosis of flank pain. <i>Scandinavian Journal of Urology</i> , 2017, 51, 342-344.	1.0	2
53	Detection of iron restriction in anaemic and nonâ€œanaemic patients: New diagnostic approaches. <i>European Journal of Haematology</i> , 2017, 99, 262-268.	2.2	11
54	Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned. <i>Dentistry Journal</i> , 2016, 4, 28.	2.3	3

#	ARTICLE	IF	CITATIONS
55	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. <i>Neuro-Oncology</i> , 2016, 18, 790-796.	1.2	67
56	Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC). <i>Clinical Oral Investigations</i> , 2016, 20, 753-758.	3.0	22
57	Concomitant Gleason Score $\geq 7$ prostate cancer is an independent prognosticator for poor survival in nonmetastatic bladder cancer patients undergoing radical cystoprostatectomy. <i>International Urology and Nephrology</i> , 2015, 47, 1789-1796.	1.4	7
58	Editorial Comment. <i>Urology</i> , 2015, 85, 746.	1.0	0
59	DHH is an Independent Prognosticator of Oncologic Outcome of Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 1842-1848.	0.4	19
60	Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2342-2355.	4.1	120
61	Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy. <i>BJU International</i> , 2012, 109, 214-219.	2.5	19
62	Intraoperative peripheral frozen sections do not significantly affect prognosis after nerve-sparing radical prostatectomy for prostate cancer. <i>BJU International</i> , 2011, 107, 755-759.	2.5	32
63	Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression <i>In vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2011, 10, 347-359.	4.1	57
64	Incidence, Clinical Symptoms and Management of Rectourethral Fistulas After Radical Prostatectomy. <i>Journal of Urology</i> , 2010, 183, 608-612.	0.4	126
65	Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate. <i>European Urology</i> , 2008, 54, 1066-1072.	1.9	147
66	Indications for Preoperative Prostate Biopsy in Patients Undergoing Radical Cystoprostatectomy for Bladder Cancer. <i>Journal of Urology</i> , 2008, 180, 1938-1941.	0.4	8
67	Anaemia in the critically ill patient: monitoring of erythropoietin therapy. <i>BJU International</i> , 2006, 97, 1161-1164.	2.5	3
68	Influence of Androgen Deprivation Therapy on the PD-L1 Expression and Immune Activity in Prostate Cancer Tissue. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	3